Replimune appoints Christy Oliger to Board effective Dec 1, 2021

Replimune Group, Inc.

Oliger appointed to Board, increasing size to 11; also joins Audit and R&D Committees.
She brings ~30 yrs pharma/biotech experience, most recently SVP Oncology at Genentech.
Receives $40k annual Board cash retainer, plus $7.5k Audit, $6k R&D; stock option for 33k shares at $28.01.
Option vests 25% on 1st anniversary, then monthly over 24 months.
Appointment effective Dec 1, 2021; will stand for election at 2022 annual meeting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christy Oliger

Director

REPL · Replimune Group, Inc.

Effective: 2021-12-01
Filed: December 2, 2021, 6:59 PM ET

the Board of Directors of the Company (the “ Board ”) increased the size of the Board from ten members to eleven and filled the newly created vacancy on the Board by appointing Christy Oliger as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christy Oliger was appointed as Director at Replimune Group, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors of the Company (the “ Board ”) increased the size of the Board from ten members to eleven and filled the newly created vacancy on the Board by appointing Christy Oliger as a director of the Company.

View on SEC.gov

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-145714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.